ORCHID ASIA VIII AIV GP LIMITED
ORCHID ASIA VIII AIV GP LIMITED is a Series C+ and buyout fund in China and Asia-Pacific writing $20M–$150M checks into consumer-services, consumer-products, outsourced-manufacturing, retailing, high-technology, media and healthcare-services.
- Stages
- Series C+, buyout
- Sectors
- consumer-services, consumer-products, outsourced-manufacturing, retailing, high-technology, media, healthcare-services
- Check size
- $20M–$150M
- Invests in
- China, Asia-Pacific
- Actively investing
- Yes
- Founded
- 1993
- Assets under management
- $1.6B
- Website
- orchidasia.com
Thesis
The firm's investment strategy centers on identifying and backing 'expanding domestic enterprises' that exhibit strong growth prospects. Key sectors of interest include consumer services and products, outsourced manufacturing, retailing, high technology, media, and healthcare services. While Orchid Asia VIII is specifically a buyout fund, the parent entity, Orchid Asia Group (established in 1993), has also engaged in venture capital investments in Southeast Asia, targeting early-to-growth stage opportunities. The typical investment ticket size for the prior fund, Orchid VII, ranged from $20 million to $150 million. The firm has a presence in Hong Kong, Shanghai, Beijing, and Guangzhou, and is domiciled in the Cayman Islands.
Common questions
Does ORCHID ASIA VIII AIV GP LIMITED invest at the Series C+ stage?
Yes. ORCHID ASIA VIII AIV GP LIMITED lists Series C+ and buyout among the stages it invests in.
What check size does ORCHID ASIA VIII AIV GP LIMITED write?
ORCHID ASIA VIII AIV GP LIMITED writes $20M–$150M checks.
Where does ORCHID ASIA VIII AIV GP LIMITED invest?
ORCHID ASIA VIII AIV GP LIMITED invests in China and Asia-Pacific.